![]() |
![]() |
Teisinis statusas
Patentas galioja
(51) | INT.CL. | C07D 471/04 | (2006.01) |
A61P 35/00 | (2006.01) | ||
A61P 37/00 | (2006.01) | ||
A61K 31/437 | (2006.01) |
(11) | Patento numeris | 3510034 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 18707612.0 |
Europos patento paraiškos padavimo data | 2018-02-16 | |
(97) | Europos patento paraiškos paskelbimo data | 2019-07-17 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2020-04-22 |
(46) | Apibrėžties vertimo paskelbimo data | 2020-08-10 |
(86) | Numeris | PCT/US2018/018484 |
Data | 2018-02-16 |
(87) | Numeris | WO 2018/152396 |
Data | 2018-08-23 |
(30) | Numeris | Data | Šalis |
201762460677 P | 2017-02-17 | US | |
201762490881 P | 2017-04-27 | US | |
201762573991 P | 2017-10-18 | US |
(72) |
GLICK, Gary, US
GHOSH, Shomir, US
ROUSH, William R., US
OLHAVA, Edward James, US
O`MALLEY, Daniel, US
|
(73) |
Innate Tumor Immunity, Inc.,
Route 206 and Province Line Road, Princeton, New Jersey 08543,
US
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Pakeistieji imidazochinolinai, kaip NLRP3 moduliatoriai |
SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS |
Mokėjimo data | Galiojimo metai | Suma | |
2025-01-02 | 8 | 185.00 EUR |
2026-02-16 |